University of Pittsburgh researchers have developed a comprehensive training program to educate health professionals on the use of FDA-approved medications for treating opioid use disorder (OUD). This training aims to improve treatment engagement, retention, and outcomes by providing detailed information on how OUD develops, the efficacy of medications for OUD (MOUD), and the essential role of case workers in patient treatment teams. The program is tailored for primary care settings and highlights the general treatment phases and best-suited MOUD for patients.
Description
The training program offers an in-depth overview of medications used to treat opioid use disorder, focusing on the changes in the brain that lead to OUD and the effectiveness of MOUD in improving patient outcomes. It emphasizes the critical role of case workers and outlines the general phases of treatment with MOUD. The content is specifically designed for health professionals in primary care settings, providing them with the knowledge needed to make informed decisions about patient care.
Applications
Tissue engineering research
High throughput screening of mechanical stimulation effects
3D tissue culture studies
Development and testing of biomaterials
Advantages
The training program is tailored for primary care health professionals, offering a comprehensive overview of FDA-approved medications for OUD. It focuses on improving treatment engagement, retention, and outcomes by highlighting the essential role of case workers in patient care. The program provides detailed information on the general treatment phases for OUD, enabling health professionals to make informed decisions about the best-suited MOUD for their patients.
Invention Readiness
The training program is fully developed and ready for implementation. It includes copyrightable text and has been created with the support of the CDC Overdose Data to Action (OD2A) grant. The program is designed to be a valuable resource for health professionals seeking to improve their understanding and treatment of opioid use disorder.
IP Status
Copyright
